

S6 Table. Pharmacokinetic parameters in human models after administration of racemic praziquantel (PZQ); includes Infected Patients (P) and Healthy Normal Volunteers (HNV). The brands, when named, were listed in subscript: (ODT): represents new racemic 150mg oral dispersion formulation (dispersed in water), BILT: Biltricide, DIS: Distocide, CYS: Cysticide formulation given with water. The superscript descriptions show the additional information of the study (a): Class A liver cirrhosis, (b): Class B liver cirrhosis, (c): Class C liver cirrhosis, (d): Fasting, (e): African population, (f): High oil content, (g): Low oil content, (h): Uraemic Patient. Unless otherwise stated the following acronyms represent; AUC: Area under the plasma concentration-time curve, A (AUC_{0-t}): Area under the plasma concentration-time curve from time zero to time t, B (AUC_{0-inf}): Area under the plasma concentration-time curve extrapolated from time zero to infinity, $t_{1/2}$: Elimination half-life, C_{max} : Peak plasma concentration, T_{max} : Time to reach peak plasma concentration following drug administration.

Drug Administered	PZQ Dose (mg/kg)	N	t _{1/2} (h)	T _{max} (h)	C _{max} (ng/ml)	AUC	
						(ng/ml/h)	(ng [*] h/ml)
PZQ ^[1]	5						
<i>HNV</i>		6	1.70	2.75	48		167 ^A
PZQ ^[1]	10						
<i>HNV</i>		6	1.30	2.58	66		209 ^A
PZQ ^[1-4]	20						
<i>HNV</i>		6	1.18	2.08	250		645 ^A
<i>HNV</i> _(BILT) ^(e)		10	0.97	1.65	846	1303, 3550	
<i>HNV</i> _(DIS) ^(e)		10	1.24	2.60	558	2133, 1563	
<i>HNV</i> _(ODT)		15	3.78	3.50	950		2569 ^B
PZQ ^[2, 4-7]	40						
<i>HNV</i> _(BILT)		1	1.28	2.75	1200	10890	
<i>HNV</i> _(BILT)		1	1.98	2.00	5000	25040	
<i>HNV</i> _(BILT)		1	1.44	2.00	2100	9840	
<i>HNV</i> _(BILT)		1	2.57	1.50	500	2760	
<i>HNV</i> _(BILT)		1	2.67	2.00	2400	13290	
<i>HNV</i> _(BILT)		1	1.98	1.25	100	2300	
<i>HNV</i> _(BILT)		1	4.30	1.75	4400	27600	
<i>HNV</i> _(BILT)		1	1.60	2.25	3600	18100	
<i>HNV</i> _(BILT)		8	1.93	1.89	2130	11750	
<i>HNV</i> _(BILT)		10	2.18	2.00	1281	1303	
<i>HNV</i> _(BILT) ^(d)		6	6.30	1.60	823	2110 ^B	
<i>HNV</i> _(BILT) ^(d)		6	2.30	2.60	978	3823 ^B	
<i>P</i> _(BILT) ^(h) (<i>haematobium</i>)		1		1.00	1040		
<i>HNV</i> _(CYS)		30	4.41	1.75	2974		10447
<i>HNV</i> _(CYS)		15	4.20	2.50	2040		8092
<i>HNV</i> _(CYS)		36	3.79	2.50	727		2066
<i>HNV</i> _(DIS)		10	2.78	1.72	685	1562	
<i>HNV</i> _(DIS) ^(d)		6	8.90	2.10	249	15928 ^B	
<i>HNV</i> _(DIS) ^(d)		8	3.30	2.60	978	4089 ^B	
<i>HNV</i> _(DIS) ^(f)		8	2.50	2.70	1570	5699 ^B	
<i>HNV</i> _(DIS) ^(g)		8	2.30	2.00	2093	7126 ^B	
<i>P</i> _(DIS) ^(a) (<i>mansoni</i>)		10		1.37	931	3870	
<i>P</i> _(DIS) ^(b) (<i>mansoni</i>)		10		2.21	1469	10720	
<i>P</i> _(DIS) ^(c) (<i>mansoni</i>)		10		3.20	3573	45350	
<i>P</i> _(DIS) ^(d, e) (<i>mansoni</i>)		9	11.90	1.60	1618	5409 ^B	
<i>P</i> _(DIS) (<i>mansoni</i>)		10		1.48	833	3023	
<i>HNV</i> _(ODT)		30	4.46	3.00	3250		9627 ^B
<i>HNV</i> _(ODT) ^(d)		14	4.89	4.50	1042		5956 ^B
PZQ ^[1]	50						
<i>HNV</i>		8	1.19	1.88	1319		3931 ^A
PZQ ^[4]	60						
<i>HNV</i> _(ODT)		15	4.32	3.5	4780		19679.5 ^B
PZQ ^[1, 8]							
<i>HNV</i>	(3 x 10)	6	0.84	2.25	65		
<i>HNV</i>	(3 x 20)	6	1.22	1.08	479		
<i>HNV</i>	(3 x 25)	6	1.30	2.25	344		
<i>HNV</i>	(3 x 25)	1	1.70			5870	
<i>HNV</i>	(3 x 25)	1	2.70			11930	
<i>HNV</i>	(3 x 25)	1	1.70			7850	
<i>HNV</i>	(3 x 25)	1	1.70			2720	
<i>HNV</i>	(3 x 25)	1	2.10			8620	
<i>HNV</i>	(3 x 25)	1	1.80			7490	
<i>HNV</i>	(3 x 25)	1	1.20			7410	
<i>HNV</i>	(3 x 25)	1	1.80			12340	

References

1. Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DH. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. *European journal of clinical pharmacology*. 1978;14(4):281-91. Epub 1978/12/01. PubMed PMID: 729622.
2. Metwally A, Bennett J, Botros S, Ebeid F, el attar Gel D. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. *Pharmacological research*. 1995;31(1):53-9. Epub 1995/01/01. PubMed PMID: 7784306.
3. Metwally A, Bennett JL, Botros S, Ebeid F. Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. *Arzneimittel-Forschung/Drug Research*. 1995;45-1(4):516-8. PubMed PMID: WOS:A1995QU77700014.
4. Bonate PL, Wang TL, Passier P, Bagehus W, Burt H, Lupfert C, et al. Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. *Journal of Pharmacokinetics and Pharmacodynamics*. 2018;45(5):747-62. doi: 10.1007/s10928-018-9601-1. PubMed PMID: WOS:000445761600008.
5. Masimirembwa CM, Naik YS, Hasler JA. The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans. *Biopharmaceutics & Drug Disposition*. 1994;15(1):33-43. doi: 10.1002/bdd.2510150103. PubMed PMID: WOS:A1994MT35100002.
6. Mandour ME, el Turabi H, Homeida MM, el Sadig T, Ali HM, Bennett JL, et al. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1990;84(3):389-93. Epub 1990/05/01. PubMed PMID: 2124391.
7. Elguiniady MA, Eltouny MA, Abdelbary MA, Abdelfatah SA, Metwally A. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. *American Journal of Tropical Medicine and Hygiene*. 1994;51(6):809-18. doi: 10.4269/ajtmh.1994.51.809. PubMed PMID: WOS:A1994QB81300014.
8. Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. *Antimicrobial agents and chemotherapy*. 1997;41(6):1256-9. doi: 10.1128/aac.41.6.1256. PubMed PMID: WOS:A1997XB71200009.